AIMS: It has been suggested that patients with T1-2 breast tumours and sentinel node (SLN) micrometastases, defined as foci of tumour cells smaller than 2 mm, may be spared completion axillary lymph node dissection because of the low incidence of further metastatic disease. To gain insight into the extent of non-sentinel lymph node (n-SLN) involvement, SLNs and complementary axillary clearance specimens in patients with SLN micrometastases were examined. METHODS: A set of 32 patients with SLN micrometastases was selected on the basis of pathology reports and review of SLNs. Five hundred and thirteen n-SLNs from the axillary clearance specimens were serially sectioned and analysed by means of immunohistochemistry for metastatic disease. Lymph node metastases were grouped as macrometastases (> 2 mm), and micrometastases (< 2 mm), and further subdivided as isolated tumour cells (ITCs) or clusters. RESULTS: In 11 of 32 patients, one or more n-SLN was involved. Grade 3 tumours and tumours > 2 cm (T2-3 v T1) were significantly associated with n-SLN micrometastases as clusters (grade: odds ratio (OR), 8.3; 95% confidence interval (CI), 1.4 to 50.0; size: T2-3 tumours v T1: OR, 15; 95% CI, 2.18 to 103.0). However, no subgroup of tumours with regard to size and grade was identified that did not have n-SLN metastases. CONCLUSIONS: In patients with breast cancer and SLN micrometastases, n-SLN involvement is relatively common. The incidence of metastatic clusters in n-SLN is greatly increased in patients with T2-3 tumours and grade 3 tumours. Therefore, axillary lymph node dissection is especially warranted in these patients. However, because n-SLN metastases also occur in T1 and low grade tumours, even these should be subjected to routine axillary dissection to achieve local control.
AIMS: It has been suggested that patients with T1-2 breast tumours and sentinel node (SLN) micrometastases, defined as foci of tumour cells smaller than 2 mm, may be spared completion axillary lymph node dissection because of the low incidence of further metastatic disease. To gain insight into the extent of non-sentinel lymph node (n-SLN) involvement, SLNs and complementary axillary clearance specimens in patients with SLN micrometastases were examined. METHODS: A set of 32 patients with SLN micrometastases was selected on the basis of pathology reports and review of SLNs. Five hundred and thirteen n-SLNs from the axillary clearance specimens were serially sectioned and analysed by means of immunohistochemistry for metastatic disease. Lymph node metastases were grouped as macrometastases (> 2 mm), and micrometastases (< 2 mm), and further subdivided as isolated tumour cells (ITCs) or clusters. RESULTS: In 11 of 32 patients, one or more n-SLN was involved. Grade 3 tumours and tumours > 2 cm (T2-3 v T1) were significantly associated with n-SLN micrometastases as clusters (grade: odds ratio (OR), 8.3; 95% confidence interval (CI), 1.4 to 50.0; size: T2-3 tumours v T1: OR, 15; 95% CI, 2.18 to 103.0). However, no subgroup of tumours with regard to size and grade was identified that did not have n-SLN metastases. CONCLUSIONS: In patients with breast cancer and SLN micrometastases, n-SLN involvement is relatively common. The incidence of metastatic clusters in n-SLN is greatly increased in patients with T2-3 tumours and grade 3 tumours. Therefore, axillary lymph node dissection is especially warranted in these patients. However, because n-SLN metastases also occur in T1 and low grade tumours, even these should be subjected to routine axillary dissection to achieve local control.
Authors: B J Czerniecki; A M Scheff; L S Callans; F R Spitz; I Bedrosian; E F Conant; S G Orel; J Berlin; C Helsabeck; D L Fraker; C Reynolds Journal: Cancer Date: 1999-03-01 Impact factor: 6.860
Authors: C Reynolds; R Mick; J H Donohue; C S Grant; D R Farley; L S Callans; S G Orel; G L Keeney; T J Lawton; B J Czerniecki Journal: J Clin Oncol Date: 1999-06 Impact factor: 44.544
Authors: Giuseppe Viale; Eugenio Maiorano; Giancarlo Pruneri; Mauro G Mastropasqua; Stefano Valentini; Viviana Galimberti; Stefano Zurrida; Patrick Maisonneuve; Giovanni Paganelli; Giovanni Mazzarol Journal: Ann Surg Date: 2005-02 Impact factor: 12.969
Authors: Andreas K Buck; Holger Schirrmeister; Torsten Mattfeldt; Sven N Reske Journal: Eur J Nucl Med Mol Imaging Date: 2004-05-04 Impact factor: 9.236
Authors: F J Fleming; D Kavanagh; T B Crotty; C M Quinn; E W McDermott; N O'Higgins; A D K Hill Journal: J Clin Pathol Date: 2004-01 Impact factor: 3.411
Authors: Carlos Martin Loza; Pablo Mandó; Carolina Ponce; Federico Coló; Veronica Fabiano; Jose Loza; Maria Victoria Costanzo; Adrian Nervo; Jorge Nadal; Anibal Nuñez de Pierro; Reinaldo Chacon; Rcm Database Contributors Journal: Breast Care (Basel) Date: 2018-07-13 Impact factor: 2.860